In Phase A, individuals will get distinctive doses and schedules of oral ABBV-744 tablet to establish Secure dosing routine. Added contributors will likely be enrolled for the identified monotherapy dosign regimen. In Segment B, individuals will get oral ruxolitinib and ABBV-744 are going to be provided as "add-on" therapy. In https://abbv-744-clinical-trial-p13467.yomoblog.com/38389668/abbv-744-as-a-potential-therapeutic-option-for-aggressive-cancers-secrets